Manuscript word count (without reference): 1700 Conclusions: New solitary FDG-positive lesions on restaging PET/CT after induction chemotherapy for NSCLC are not rare in good responders to chemotherapy. In our experience, all these lesions were not associated with malignancy.
Introduction
Patients with clinical stage III-N2 or -T4 non-small cell lung cancer (NSCLC) have a poor prognosis when treated with surgery alone. In order to improve outcome, the concept of preoperative induction therapy was introduced. It has been shown that induction chemotherapy (or radiochemotherapy) combined with surgery is effective in selected subgroups of patients such as patients with IIIA N2 disease [1, 2] . Recent studies suggested that mediastinal down staging and complete resection after induction are significant factors for better outcome in cases of stage IIIA or IIIB disease. But several reports have also described an increased perioperative morbidity and mortality for surgical resection following induction therapy compared with resection without induction treatment [3] . Therefore, restaging after induction therapy plays a central role in selecting candidates for resection. 18 Fluoro-2-deoxy-D-glucose positron-emission tomography with integrated computed-tomography (FDG-PET/CT) has become widely adopted as a major tool for the staging of NSCLC and has been increasingly incorporated into the routine work-up for restaging after induction therapy. However, due to a poor sensitivity of 50% to 60%, PET scan for mediastinal restaging is not as accurate as prior to induction [4] [5] [6] [7] [8] .
In this study, we assessed the significance of new solitary FDG-positive lesions on restaging PET/CT located in lymph nodes or in the contralateral lung in patients who showed a good radiological response in the primary tumor and in the mediastinal nodes after induction therapy. 
Materials and Methods

Between
Results
Restaging PET/CT revealed a new solitary focal abnormality in 6/31 (20%) patients after induction therapy. Characteristics of these 6 patients, histology, clinical stage of the disease and location of the primary are shown in Table 1 . Induction treatment could be completed in all patients. Transient neutropenia and gastroenteritis were observed in one patient.
In all patients, restaging PET/CT showed an important decrease of the FDG-uptake in the primary tumor as well as in the mediastinal lymph nodes which were strongly PET-positive before induction treatment. Despite the small number of patients, the decrease of SUV max was significant for the primary tumor (non parametric Wilcoxon test). Table 2 gives the values of SUV max in the primary and in the lymph nodes before and after induction therapy. This radiological response to chemotherapy could be confirmed histopathologically by the presence of necrosis in the operative specimen. Median necrosis values for the primary tumor and for the lymph nodes were 45% and 20%, respectively.
The 6 new focal abnormalities revealed at restaging PET/CT after induction chemotherapy were located in an ipsilateral cervical lymph node in 2 patients, in the contralateral upper lobe in 2 patients and in a contralateral paratracheal lymph node and an ipsilateral mammary internal lymph node in 1 patient, respectively (Table 3) 
Discussion
In the nineteens, induction therapy including preoperative radiochemotherapy or chemotherapy alone has been increasingly used for locally advanced stage III NSCLC in order to downstage tumors and render them completely resectable [9, 10] . Several studies have shown a strong survival benefit in patients with stage IIIA-N2 disease who have been down staged by induction therapy in comparison with patients with residual N2 disease [1, 2] . It has also been shown that surgery can be performed in a curative intent in highly selected patients with stage IIIB-T4 disease within a multimodality therapy concept. The most important prognostic factors are complete resection and the absence of mediastinal lymph node involvement. As a consequence, accurate restaging after induction therapy is of a paramount importance in these subgroups of patients. The difficulty is to assess the pathologic response after induction treatment. In many centers re-staging CT alone is performed despite its low accuracy in restaging the mediastinum. Its sensitivity varied from 41% to 59% and its specificity from 75% to 62% with an accuracy of 58% and 60% [11, 12] . More invasive techniques such as predictive value, sensitivity, specificity and diagnostic accuracy of EUS-FNA in this small group of patients were 100%, 67%, 75%, 100% and 83%, respectively [13] . More recently, Herth et al.
published the results of a large trial evaluating EBUS-TBNA in restaging the mediastinum after induction chemotherapy in 124 patients with NSCLC. Overall sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy were 76%, 100%, 100%, 20% and 77%. Therefore, the authors recommended the need to confirm EBUS-FNA tumor-negative mediastinal nodes by surgical staging before thoracotomy [14] . Repeated mediastinoscopy, although technically more difficult than the first procedure due to adhesions and mediastinal fibrosis is technically feasible in experienced hands [15] . In different series, its sensitivity after induction therapy for mediastinoscopy proven N2 disease was reported from 70% to 78% except in one prospective study with a reported sensitivity to detect mediastinal disease of 29% [11, 12, [16] [17] [18] . This low sensitivity was largely explained by the fact that biopsy of the subcarinal nodes was not adequately performed in 2/3 of patients.
.
In our study, we used whole body integrated PET/CT for restaging in 31 patients. Accuracy of PET/CT was assessed in different settings related to induction protocol (chemotherapy or chemoradiotherapy), timing of imaging (from one to ten weeks post-induction) and interpretation of imaging (visual or standardized uptake value). Its sensitivity and specificity in three different studies were 77 and 92%, 73 and 89%, 62 and 88%, respectively [12, 19, 20] . Although accuracy of PET/CT in restaging is lower than for staging untreated patients, it enables the direct correlation of FDGaccumulating lesions with morphologic structures throughout the body. It has also been showed that the comparison of SUVmax values before and after induction treatment allowed prediction of histopathologic response in the primary tumor and in the mediastinal lymph nodes, therefore carrying an important prognostic value [19, 21] . In the present study, restaging PET/CT showed a marked New solitary high FDG accumulation in lymph node or contralateral parenchymal lung on restaging PET-CT after induction chemotherapy in good responders with locally advanced NSCLC were not rare (6/31 or 20%). In our experience, these FDG-positive lesions did not imply progression of the disease since they were diagnosed as benign lesions in all 6 patients. Therefore extensive diagnostic procedures for these lesions could be avoided in the future if larger studies confirm our findings. 
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